Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Launched by ANHUI PROVINCIAL HOSPITAL · Dec 25, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two special imaging agents, [18F]AlF-PSMA-N5 and [18F]F-DCFPyL, to see which one is better at detecting prostate cancer, including when it comes back or spreads to other parts of the body. Researchers want to learn how well these agents work in different organs of patients who have prostate cancer. The trial is currently looking for male participants aged 18 to 90 who have been diagnosed with prostate cancer or are suspected of having it again after treatment. Participants must also be willing to have a needle biopsy or surgery to confirm their diagnosis after the imaging tests.

If you decide to join this study, you'll undergo both types of imaging tests within two weeks, which will help the doctors understand how the new agent works compared to the standard one. It’s important to note that some people will not be eligible to participate, such as those with certain health conditions or other types of cancer. Overall, this trial aims to improve the way prostate cancer is diagnosed and monitored, which could help many patients in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Aged from 18 to 90 years old;
• • Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);
• • Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
• • simultaneous \[18F\]AlF-PSMA-N5 and \[18F\]F-DCFPyL examinations within two weeks;
• • Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;
• • Sign informed consent.
• Exclusion Criteria:
• • Patients who cannot cooperate with the examination;
• • Concurrent malignant tumors;
• • Previous alcohol allergy;
• • Patients with liver and kidney dysfunction;
• • Other circumstances deemed by the investigator to be inappropriate for trial participation.